Brief description of study

This is a Phase 3, multi-center, randomized withdrawal study to evaluate the sustained
benefit in efficacy and safety of TD-9855 in subjects with primary autonomic failures
(MSA, PD, or PAF) and snOH. Eligible subjects are either (i) completers of Study 0169 (0169 Completers Group), or (ii) snOH subjects meeting all applicable study inclusion criteria and none of the applicable exclusion criteria (De Novo Group).
The study consists of 3 periods: (i) 16-week open-label (OL) treatment with TD-9855,
(ii) 6-week randomized placebo-controlled treatment, and (iii) 2-week follow-up (only for
patients who do not enroll in Study 0171). A 2-week screening period will apply to the
De Novo Group only.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.